Prostate Cancer Trial, Recruiting NCT06335914 Sponsor: University Health Network, Toronto Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06335914
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men aged 18 or older
  • People who have been confirmed through tissue or cell testing to have prostate cancer (specifically a type called adenocarcinoma)
  • People who are considered "poor risk" and have prostate cancer that has spread to other parts of the body (metastatic), and who have not yet been treated or have had a return of the cancer
  • People with a high amount of cancer spread, confirmed by standard imaging scans (CT or MRI, plus a bone scan), taken before starting hormone therapy and a specific type of cancer-blocking medication
  • People with either a high or low amount of cancer spread, plus a PSA level of 4.0 or above after 6 to 8 months of starting hormone therapy
  • People who are willing to have specialised PET scans as part of the study, and who receive ongoing care from a cancer specialist, radiation specialist, or urologist at Princess Margaret Cancer Centre
  • People who have not had a PSMA or FDG PET scan in the 60 days before each scheduled scan in the study
  • People already taking part in other clinical trials may be eligible if all other criteria are met

Who may not be able to join:

  • People taking part in a randomised controlled trial where it is unknown which treatment they are receiving
  • People who are unable to undergo or complete the required PSMA PET and FDG PET scans
  • People who are unable to provide written consent themselves or through a legal representative
  • People whose treating doctor considers that their overall health or other conditions would seriously affect their ability to follow the study procedures or attend follow-up appointments
  • People with serious uncontrolled health conditions that could affect the safety of the scans or make the scan results difficult to interpret (confirm with trial site)
  • People with another active cancer diagnosis
  • People currently on dialysis
  • People who have received another radioactive substance or experimental treatment within a certain period before the PET scans (specifically within 5 half-lives of that substance — confirm with trial site for exact timeframes)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Di (Maria) Jiang, Princess Margaret Cancer Centre/University Health Network

Phone: 416-946-4501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 April 2025
Est. completion
4 March 2029

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Proportion of patients with high volume mCSPC having PSMA avid disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov